Mammoth Biosciences disclosed preclinical monkey data and plans for a first‑in‑human study of an in vivo gene editing candidate designed to durably lower triglycerides. The program uses Mammoth’s gene‑editing platform to target hepatic pathways that control lipid metabolism and aims to provide a one‑time intervention for cardiovascular risk reduction. The company presented early safety and efficacy signals in nonhuman primates and is preparing regulatory filings and the clinical protocol for human dosing.